All In Biotech

Drug Trial Radar · NCT04971226

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 405 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

405

Actual

Start

Oct 6, 2021

Primary completion

Nov 28, 2023

Study completion Jan 18, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected Tyrosine Kinase Inhibitor (TKI) for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP. The Investigator selected TKI will be one of the following treatment options for first-line treatment of CML-CP - imatinib 400 mg QD or nilotinib 300 mg BID or dasatinib 100 mg QD or bosutinib 400 mg QD. This study has three periods: 1. Treatment period for all randomized participants, 2. Optional Treatment-Free Remission (TFR) period only for participants meeting TFR eligibility criteria and 3. Treatment Re-Initiation (TRI) period only for participants who relapsed after TFR attempt.

Conditions

  • Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

Interventions

  • ImatinibDrug

    Comes in 100 mg and 400 mg tablets and taken orally

  • NilotinibDrug

    Comes in 150 mg and 200 mg capsules and taken orally

  • BosutinibDrug

    Comes in 100 mg and 400 mg tablets and taken orally

  • DasatinibDrug

    Comes in 20 mg, 50 mg, 70 mg and 100 mg tablets and taken orally

  • AsciminibDrug

    Comes in 40 mg tablets and taken orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKITime frame: At 48 weeks
  2. Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Asciminib (Imatinib Stratum) vs Investigator Selected TKI (Imatinib Stratum)Time frame: At 48 weeks

Locations

110 sites in 29 countries. Site status is shown where the registry gives one.

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Florida Cancer Specialists

    Fort Myers, Florida

  • Florida Cancer Specialists Pan

    Tallahassee, Florida

  • University of Kentucky

    Lexington, Kentucky

  • Uni of Massachusetts Medical Center

    Worcester, Massachusetts

  • Wake Forest University Baptist Medical Center

    Winston-Salem, North Carolina

  • Williamette Cancer Center

    Eugene, Oregon

  • Oregon Health Sciences University

    Portland, Oregon

  • Avera Cancer

    Sioux Falls, South Dakota

  • Chattanooga Onc And Hem Assoc PC

    Chattanooga, Tennessee

  • Texas Oncology

    Amarillo, Texas

  • Texas Oncology-Baylor USO

    Dallas, Texas

  • Texas Oncology

    Dallas, Texas

  • Novartis Investigative Site

    Southport, Australia

  • Novartis Investigative Site

    Kingswood, New South Wales, Australia

  • Novartis Investigative Site

    Port Macquarie, New South Wales, Australia

  • Novartis Investigative Site

    Adelaide, South Australia, Australia

  • Novartis Investigative Site

    Linz, Upper Austria, Austria

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Leuven, Vlaams Brabant, Belgium

  • Novartis Investigative Site

    Varna, Bulgaria

  • Novartis Investigative Site

    Calgary, Alberta, Canada

  • Novartis Investigative Site

    Hamilton, Ontario, Canada

  • Novartis Investigative Site

    Ottawa, Ontario, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Lanzhou, China

  • Novartis Investigative Site

    Tianjin, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Shenzhen, Guangdong, China

  • Novartis Investigative Site

    Zhengzhou, Henan, China

  • Novartis Investigative Site

    Wuhan, Hubei, China

  • Novartis Investigative Site

    Nanjing, Jiangsu, China

  • Novartis Investigative Site

    Suzhou, Jiangsu, China

  • Novartis Investigative Site

    Xian, Shanxi, China

  • Novartis Investigative Site

    Chengdu, Sichuan, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, China

  • Novartis Investigative Site

    Wenzhou, Zhejiang, China

  • Novartis Investigative Site

    Brno, Czechia

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.